NRAS Mutation Test: Melanoma, Colon Cancer, and Results

An NRAS mutation test looks for acquired tumor changes that keep the RAS–MAPK growth pathway active. It is most often included in molecular testing for advanced melanoma and metastatic colorectal cancer, although NRAS alterations occur in other tumors. In melanoma, an NRAS mutation identifies a major molecular subtype, usually after or alongside BRAF testing. It can shape clinical-trial options and help explain why a BRAF-targeted treatment is not appropriate, but there is no standard direct NRAS inhibitor approved for routine melanoma care. In colorectal cancer, the result has a more immediate exclusionary role: a pathogenic NRAS mutation predicts lack of benefit from anti-EGFR antibodies such as cetuximab or panitumumab. Testing must cover the clinically relevant RAS hotspots, not only one codon or exon. A negative result means no covered NRAS mutation was detected; it does not mean the tumor lacks all drivers or will definitely respond to a particular drug. Tissue quality, tumor percentage, test coverage, and other biomarkers remain essential.

• In metastatic colorectal cancer, a pathogenic NRAS mutation generally means anti-EGFR antibody therapy should not be used.
• NRAS mutations occur in about 15%–20% of cutaneous melanomas and are usually mutually exclusive with BRAF V600 mutations.
• Common actionable testing regions include NRAS exons 2, 3, and 4, especially codons 12, 13, 59, 61, 117, and 146.
• A negative blood-based result may need tissue testing when circulating tumor DNA is too low.
• NRAS positivity is a tumor biomarker, not usually an inherited cancer-risk result.

Table of Contents

• What NRAS Mutations Do
• When Testing Is Ordered
• Tissue, Blood, and Test Methods
• Reading Positive and Negative Results
• NRAS in Melanoma
• NRAS in Colorectal Cancer
• Treatment and Resistance
• Limitations and Next Steps

What NRAS Mutations Do

NRAS encodes a small GTPase that acts like a molecular switch. In its normal cycle, NRAS turns on after a growth signal reaches a cell-surface receptor and turns off after converting GTP to GDP. Pathogenic hotspot mutations reduce this shutoff activity, leaving downstream pathways such as RAF–MEK–ERK and PI3K–AKT active. The result is continued cell growth and survival signaling.

Most tumor-driving NRAS variants occur at codons 12, 13, or 61, with codon 61 especially common in melanoma. Colorectal testing also needs less common but clinically relevant changes at codons 59, 117, and 146. Reports may use notation such as NRAS c.182A>G (p.Q61R). The exact amino-acid change matters because a broad statement such as “RAS positive” can hide whether the alteration was in KRAS or NRAS and whether it was a validated activating variant.

NRAS testing in cancer is usually somatic. The mutation is detected in tumor tissue or circulating tumor DNA and generally arose in the cancer. It does not imply that relatives inherited the variant. Rare germline NRAS variants cause developmental RASopathies, but those conditions are not diagnosed from routine adult tumor profiling.

NRAS is part of a larger signaling network. A tumor can activate the pathway through BRAF, KRAS, receptor tyrosine kinases, NF1 loss, or other mechanisms. Driver alterations are often mutually exclusive in untreated tumors because one strong pathway activator is enough, but co-alterations and resistant subclones can appear, especially after therapy.

The result has tumor-specific meaning. In melanoma, NRAS defines biology and may guide trials or sequencing of systemic therapy. In colorectal cancer, any activating KRAS or NRAS mutation is treated as RAS-mutant for anti-EGFR selection. The same variant should not be assigned one universal treatment meaning across all cancers.

When Testing Is Ordered

For melanoma, molecular testing is most important in unresectable stage III or stage IV disease and may also be performed in high-risk resected disease when results could affect therapy or trials. BRAF V600 is usually the first essential target because approved BRAF/MEK combinations require an appropriate BRAF alteration. NRAS and KIT testing may follow or be included in a broader panel, especially when BRAF is wild type.

For metastatic colorectal cancer, extended RAS testing is standard before considering cetuximab or panitumumab. “Extended” means KRAS and NRAS exons 2, 3, and 4, not only KRAS codons 12 and 13. Testing may be done on the primary tumor or a metastasis because early driver mutations are usually concordant, though a recent metastatic specimen can better reflect current tumor biology when available.

Other reasons include:

• enrollment in a clinical trial of RAS-, MEK-, ERK-, SHP2-, or combination therapy;
• clarification of an ambiguous molecular profile;
• repeat profiling after acquired resistance;
• identifying a driver in thyroid cancer or another tumor where NRAS can occur;
• broad solid-tumor NGS panel testing for advanced cancer.

Testing is not usually needed for every early-stage melanoma or localized colorectal cancer if it cannot change management. In colorectal cancer, however, other biomarkers such as mismatch repair status are important even in earlier stages for Lynch screening and prognosis. The order should match the disease stage and clinical decision.

A pathologist selects a block with enough viable tumor. If an old specimen is depleted, decalcified, or very small, a new biopsy or blood-based assay may be considered. Treatment urgency, biopsy risk, and likelihood of tumor DNA shedding influence the choice.

Tissue, Blood, and Test Methods

Formalin-fixed paraffin-embedded tumor tissue is the usual specimen. The laboratory estimates tumor percentage and may macrodissect the marked area. Blood-based liquid biopsy analyzes circulating tumor DNA (ctDNA), which can provide a faster and less invasive profile in metastatic disease.

Method	Coverage	Advantage	Limitation
Allele-specific PCR	Selected hotspots	Fast and sensitive for known variants	Misses mutations outside the targeted list
Pyrosequencing or Sanger sequencing	Defined exons	Direct sequence information	May require higher tumor percentage
Targeted NGS	NRAS plus many cancer genes	Efficient broad profiling	Coverage and detection limits vary by panel
Plasma ctDNA NGS	Multiple genes in blood	Avoids tissue biopsy and can capture several metastases	False negatives occur with low DNA shedding

A report should state the genomic regions tested. A panel that reports “NRAS negative” but covers only codons 12, 13, and 61 is incomplete for colorectal anti-EGFR selection because codons 59, 117, and 146 also matter. The clinical indication should be given to the laboratory so the right coverage and interpretation are used.

Variant allele fraction is the percentage of sequence reads carrying the mutation. It is influenced by tumor purity, copy number, ctDNA shedding, and clonal structure. A 5% plasma VAF is not a 5% response probability or the percentage of the body affected by cancer. Low VAF can represent a small subclone or simply diluted tumor DNA.

A negative plasma result is most reliable when the assay detects other tumor-derived alterations or reports an adequate tumor fraction. When no mutations are found and the disease is known to shed little ctDNA, tissue testing is preferred. A positive plasma finding is often highly informative, but rare clonal hematopoiesis variants and technical artifacts require laboratory filtering and clinical correlation.

Reading Positive and Negative Results

A pathogenic NRAS mutation detected result means the tumor contains a recognized activating variant. The report should identify the codon and classification. In metastatic colorectal cancer, the result classifies the cancer as RAS-mutant for anti-EGFR treatment decisions. In melanoma, it identifies an NRAS-mutant subtype but does not point to one routinely approved NRAS-specific drug.

A not-detected result means no covered variant was found above the assay limit. It does not automatically mean “RAS wild type” unless both KRAS and NRAS were tested across all required exons. It also does not prove sensitivity to anti-EGFR therapy; BRAF V600E, HER2 amplification, right-sided primary location, rare fusions, tumor heterogeneity, and other mechanisms can reduce benefit.

A variant of uncertain significance should not be treated like a known activating hotspot. Rare non-hotspot substitutions may lack functional evidence. The laboratory may update classification as data accumulate. Treatment should follow validated biomarkers rather than speculation from a VUS.

An equivocal or low-quality result may reflect low tumor percentage, degraded DNA, sequencing artifacts, or insufficient coverage. The next step can be another block, a metastatic biopsy, repeat extraction, or plasma testing. Repeating the same inadequate specimen without changing the problem often adds little.

Sometimes a report shows both NRAS and another apparent driver. The team should consider whether one alteration is subclonal, acquired after treatment, or a technical artifact. Broad profiling and review of VAFs, copy number, treatment history, and sample timing can clarify the biology.

NRAS in Melanoma

NRAS mutations occur in roughly 15%–20% of cutaneous melanomas, making NRAS the second most common established driver after BRAF. Q61R, Q61K, and Q61L are frequent. NRAS-mutant melanoma is often associated with chronic sun damage, thicker primary tumors, and a tendency toward aggressive clinical behavior in some cohorts, but an individual prognosis still depends on stage, tumor burden, sites of spread, lactate dehydrogenase, performance status, and treatment response.

NRAS and BRAF V600 mutations are usually mutually exclusive. A confirmed NRAS mutation helps explain why BRAF inhibitor monotherapy or a BRAF/MEK combination designed for BRAF V600 melanoma is not appropriate. Giving a BRAF inhibitor to an NRAS-mutant tumor can paradoxically activate MAPK signaling in some settings.

Immune checkpoint inhibitors remain central systemic therapy for advanced NRAS-mutant melanoma. Options may include anti-PD-1 therapy alone or combination immunotherapy, chosen according to disease tempo, toxicity tolerance, brain metastases, and other factors. NRAS status does not guarantee response or resistance to immunotherapy.

MEK inhibition has shown activity in NRAS-mutant melanoma, but the benefit has been modest and has not established a universally approved direct standard comparable with BRAF/MEK therapy in BRAF V600 disease. Clinical trials are evaluating combinations that target MEK, ERK, SHP2, RAF dimers, cell-cycle pathways, and emerging RAS strategies.

If the melanoma progresses, repeat tumor molecular profiling may identify a trial target or a new resistance mechanism. A new biopsy can also confirm that a changing lesion is melanoma rather than another process.

NRAS in Colorectal Cancer

NRAS mutations are less common than KRAS mutations in colorectal cancer, generally occurring in a few percent of metastatic cases. Their treatment meaning is nevertheless strong: activating NRAS mutations predict resistance to anti-EGFR monoclonal antibodies. This applies across the extended RAS testing regions, not only codon 61.

Anti-EGFR therapy works by blocking signaling from the epidermal growth factor receptor. When NRAS is already locked on downstream, blocking the receptor cannot reliably shut off the pathway. The mutation is therefore a negative predictive biomarker. It helps avoid ineffective treatment and unnecessary skin, electrolyte, infusion, and gastrointestinal toxicity.

A RAS-wild-type result is necessary but not sufficient for benefit. Primary tumor sidedness matters: patients with left-sided RAS-wild-type metastatic colorectal cancer generally derive more benefit from first-line anti-EGFR therapy than those with right-sided primaries. BRAF V600E, HER2 amplification, MSI-H/dMMR, and other findings can direct treatment elsewhere.

At resistance, a previously RAS-wild-type cancer can develop KRAS or NRAS-mutant subclones. Plasma ctDNA may detect these changes and show their decline after anti-EGFR withdrawal. In selected research or clinical contexts, this dynamic information can help evaluate anti-EGFR rechallenge, but thresholds and timing should follow validated protocols.

The report should be reviewed with a KRAS mutation test, BRAF, HER2, and MSI/MMR results. A portal entry showing only “NRAS negative” is not enough to establish the complete metastatic colorectal biomarker profile.

Treatment and Resistance

NRAS is difficult to inhibit directly because its protein surface and biochemical cycle differ from some druggable mutant proteins. New approaches include mutation-selective or pan-RAS inhibitors, RAS-ON inhibitors, SHP2 inhibitors, SOS1 inhibitors, RAF dimer inhibitors, ERK inhibitors, and rational combinations. Most remain clinical-trial strategies and may have tumor-specific eligibility rules.

In melanoma, systemic treatment usually begins with immunotherapy unless clinical circumstances favor another approach. Local treatments such as surgery, radiation, or ablation may be appropriate for limited disease. Brain metastases require coordinated systemic and local planning. NRAS status is one component, not a replacement for staging.

In colorectal cancer, NRAS positivity redirects treatment away from cetuximab or panitumumab. Chemotherapy combinations, anti-VEGF therapy, immunotherapy for MSI-H/dMMR tumors, BRAF-targeted therapy for BRAF V600E, HER2-targeted therapy for HER2-positive RAS-wild-type disease, and other options depend on the broader profile. The NRAS result excludes one pathway more clearly than it selects a single alternative.

Resistance can be primary, present before treatment, or acquired, emerging under selective pressure. A tissue biopsy samples one lesion, while plasma may capture DNA from several. Discordant results should be examined in the context of timing, tumor burden, and assay sensitivity rather than assuming one is wrong.

Limitations and Next Steps

The biggest limitations are incomplete coverage and overinterpretation of a negative result. Ask whether the assay covered all clinically required NRAS exons and whether KRAS was included. For melanoma, ask whether BRAF and KIT were assessed and whether the histologic subtype suggests other fusions or mutations.

Tumor heterogeneity, old tissue, low tumor percentage, decalcification, and low ctDNA shedding can cause false negatives. A highly sensitive hotspot assay can miss a rare mutation outside its menu, while a broad NGS panel can have lower sensitivity for tiny subclones. The best method depends on the question.

Questions to ask include:

• What exact NRAS variant was found, and is it a validated activating hotspot?
• Was this tissue or plasma, and what was the tumor fraction?
• Did the test cover exons 2, 3, and 4 for colorectal cancer?
• Are KRAS, BRAF, MSI/MMR, and HER2 results complete?
• Does the mutation exclude a proposed drug or create a clinical-trial option?
• Should a negative plasma result be confirmed in tissue?
• Would repeat testing at progression change treatment?
• Is the finding somatic, and is any separate hereditary test indicated from my history?

Keep the full report with the specimen date. Tumor profiles are time-stamped snapshots; a result obtained before several lines of therapy may not represent all resistant clones years later. Decisions should use the most relevant adequate sample and current disease-specific guidelines.

Examples of how the same result leads to different decisions

Consider a metastatic melanoma with NRAS Q61R, no BRAF V600 mutation, and several rapidly growing lesions. The NRAS result rules out standard BRAF V600-targeted therapy, but the first systemic discussion still centers on immune checkpoint therapy, brain imaging, symptom burden, and clinical-trial access. A trial may require the exact Q61 variant, measurable disease, prior immunotherapy, and adequate organ function.

Now consider a left-sided metastatic colon cancer with NRAS Q61K. Here, the result directly excludes cetuximab and panitumumab because the downstream pathway is active. The oncologist chooses among chemotherapy, anti-VEGF therapy, and any options created by MSI-H, BRAF, HER2, KRAS G12C, or other findings. A high PD-L1 score would not override the RAS resistance rule for anti-EGFR therapy.

A third scenario is a colorectal tumor reported as “NRAS wild type” on an old assay that tested only codons 12, 13, and 61. Before anti-EGFR treatment, the team should verify extended KRAS/NRAS exons 2, 3, and 4. Reanalysis of the existing block may be enough; a new biopsy is not always necessary.

Quality checks for tissue and plasma

For tissue, review the tumor percentage and whether the specimen was collected before or after major treatment. A small primary biopsy may be adequate for a clonal driver, but a recent progressing metastasis can reveal resistant subclones. Necrosis, melanin, mucin, and decalcification can interfere with extraction or amplification.

For plasma, look for evidence that tumor DNA was present. If the assay detects several credible tumor variants but no NRAS, the negative result is stronger. If it detects nothing at all, especially in low-volume lung-only or peritoneal disease, the sample may be noninformative. Tissue reflex testing prevents a false-negative plasma result from opening an inappropriate anti-EGFR option.

At acquired resistance, plasma can show several different RAS mutations at low fractions, reflecting parallel resistant clones. These may decline after stopping anti-EGFR therapy. Rechallenge strategies require more than a simple “currently negative” call; validated protocols consider the absence of resistance alterations, elapsed time, prior benefit, tumor sidedness, and other biomarkers.

Patients should keep the original variant and date because “RAS status” can change in the detectable circulating population after treatment even though the founding tumor history remains important. The oncology note should state whether the result was baseline or resistance testing.

How pathology subtype changes the testing strategy

Not all melanomas have the same driver distribution. Acral and mucosal melanomas have lower BRAF and NRAS frequencies than common sun-exposed cutaneous melanoma and are more likely to carry KIT or structural alterations. Uveal melanoma is usually driven by GNAQ, GNA11, CYSLTR2, or PLCB4 rather than NRAS. A result must therefore be interpreted against the exact melanoma subtype.

In colorectal cancer, pathology confirms adenocarcinoma and provides primary-site information. A right-sided tumor has different average biology and anti-EGFR benefit than a left-sided tumor even when extended RAS is wild type. Mucinous and poorly differentiated features can be associated with MSI or BRAF pathways, prompting complete biomarker review.

A new NRAS mutation detected only after anti-EGFR exposure can represent acquired resistance rather than the original dominant clone. Its low VAF does not make it irrelevant, but the team should confirm that the assay can distinguish true variants from sequencing noise. Serial plasma values can show clonal decay, yet treatment decisions should follow validated rechallenge criteria.

For trial enrollment, check whether eligibility requires any activating NRAS mutation or only codon 61, melanoma histology, a specified prior therapy, and measurable disease. A biologically plausible target does not guarantee that a trial accepts every variant or tumor type.

Sun protection and skin surveillance remain important after melanoma treatment because NRAS status does not prevent a second primary melanoma. In colorectal cancer, surveillance after surgery or systemic therapy follows stage and response rather than the NRAS mutation. The tumor result guides selected drugs, while routine imaging, colonoscopy, carcinoembryonic antigen, and symptom review follow disease-specific plans.

A negative NRAS result is only as reliable as the tested material and assay coverage. Low tumor percentage, necrosis, decalcification, or limited exon coverage can reduce sensitivity. When the result conflicts with the pathology or treatment context, repeat testing or a broader validated panel may be appropriate.

References

• Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2025 (Guideline)
• Updates of CSCO guidelines for colorectal cancer version 2025 2025 (Guideline Update)
• RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor Monoclonal Antibody Therapy 2025 (Official Measure)
• Targeting NRAS Mutant Melanoma: Current Challenges and Future Perspectives 2021 (Review)
• Melanoma Treatment (PDQ®)–Health Professional Version 2025 (Official Review)

Disclaimer

This article provides general information about somatic NRAS testing and cannot determine treatment for an individual cancer. Results must be reviewed with the complete pathology, stage, specimen quality, and other biomarkers by an oncology team. Do not start or stop targeted or immune therapy based on a portal result alone.